Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

DY8:GR

24.151 EUR 0.094 0.39%

As of 09:35:13 ET on 05/28/2015.

Snapshot for Dyax Corp (DY8)

Open: 23.993 Day's Range: 23.993 - 24.163 Volume: 0
Previous Close: 24.245 52wk Range: 5.732 - 28.500 1-Yr Rtn: +292.64%

Stock Chart for DY8

No chart data available.
  • DY8:GR 24.155
  • 1D
  • 1M
  • 1Y
24.245
Interactive DY8 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for DY8

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) -0.1910
Est. PEG Ratio -
Market Cap (M EUR) 3,515.84
Shares Outstanding (M) 145.67
30 Day Average Volume 174
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 07/29/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for DY8

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for DY8

Dyax Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of antibodies, small proteins and peptides as therapeutic products for unmet medical needs, particularly in the areas of inflammation and oncology. The Company currently has two recombinant proteins, DX-88 and DX-890 in phase II clinical trials.

Gustav A ChristensenPresident/CEOGeorge V MigauskyExec VP/CFO
Burt A AdelmanExec VP/Chief Medical OfcrTodd BazemoreExec VP/Chief Commercial Ofcr
More Company Profile & Key Executives for DY8

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil